Search Results - "BRESNIK, Mark"

Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High–Loading Dose Regimen with Standard Dosing (AmBiLoad Trial) by Cornely, Oliver A., Maertens, Johan, Bresnik, Mark, Ebrahimi, Ramin, Ullmann, Andrew J., Bouza, Emilio, Heussel, Claus Peter, Lortholary, Olivier, Rieger, Christina, Boehme, Angelika, Aoun, Mickael, Horst, Heinz-August, Thiebaut, Anne, Ruhnke, Markus, Reichert, Dietmar, Vianelli, Nicola, Krause, Stefan W., Olavarria, Eduardo, Herbrecht, Raoul

“…Background.Treatment of invasive mold infection in immunocompromised patients remains challenging. Voriconazole has been shown to have efficacy and survival…”
Get full text

2516. Development of a de novo Patient-Reported Outcome (PRO) Measure to Assess the Impacts of Disseminated Coccidioidomycosis [Valley Fever] on Patients Living with the Condition by Harvey, Emma L, Bresnik, Mark, Symonds, Tara, Blatt, Elliott, Hughes, Sophie, Purdie, Rob, Clegg, Jennifer L

“…Abstract Background Extrapulmonary or disseminated coccidioidomycosis (cocci) is a rare, severe form of fungal disease acquired by inhaling spores of…”
Get full text

Pseudomonas aeruginosa Susceptibility Patterns and Associated Clinical Outcomes in People with Cystic Fibrosis following Approval of Aztreonam Lysine for Inhalation by Keating, Claire L, Zuckerman, Jonathan B, Singh, Pradeep K, McKevitt, Matthew, Gurtovaya, Oksana, Bresnik, Mark, Marshall, Bruce C, Saiman, Lisa

“…The approval of aztreonam lysine for inhalation solution (AZLI) raised concerns that additional antibiotic exposure would potentially affect the susceptibility…”
Get full text

ALPINE2: Efficacy and safety of 14-day vs 28-day inhaled aztreonam for Pa eradication in children with cystic fibrosis by Gilchrist, Francis J., Bui, Stephanie, Gartner, Silvia, McColley, Susanna A., Tiddens, Harm, Ruiz, Gary, Stehling, Florian, Alani, Muhsen, Gurtovaya, Oksana, Bresnik, Mark, Watkins, Timothy R., Frankovic, Biliana, Skov, Marianne

“…•28-day AZLI is indicated to treat P. aeruginosa (Pa) infection in people with CF.•28-day nebulized treatment eradication protocols can be burdensome for…”
Get full text

Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia by Cornely, Oliver A, Leguay, Thibaut, Maertens, Johan, Vehreschild, Maria J G T, Anagnostopoulos, Achilles, Castagnola, Carlo, Verga, Luisa, Rieger, Christina, Kondakci, Mustafa, Härter, Georg, Duarte, Rafael F, Allione, Bernardino, Cordonnier, Catherine, Heussel, Claus Peter, Morrissey, C Orla, Agrawal, Samir G, Donnelly, J Peter, Bresnik, Mark, Hawkins, Michael J, Garner, Will, Gökbuget, Nicola

“…To prevent invasive fungal disease (IFD) in adult patients undergoing remission-induction chemotherapy for newly diagnosed acute lymphoblastic leukaemia (ALL)…”
Get full text

Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial by Assael, Baroukh M, Pressler, Tacjana, Bilton, Diana, Fayon, Michael, Fischer, Rainald, Chiron, Raphael, LaRosa, Mario, Knoop, Christiane, McElvaney, Noel, Lewis, Sandra A, Bresnik, Mark, Montgomery, A. Bruce, Oermann, Christopher M

“…Abstract Background Open-label, parallel-group, international trial comparing aztreonam for inhalation solution (AZLI) and tobramycin nebulizer solution (TNS)…”
Get full text

Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis by Flume, Patrick A, Clancy, John P, Retsch-Bogart, George Z, Tullis, D. Elizabeth, Bresnik, Mark, Derchak, P. Alex, Lewis, Sandra A, Ramsey, Bonnie W

“…Abstract Background Inhaled antibiotics are standard of care for treating chronic pseudomonal respiratory infections in cystic fibrosis patients, initially…”
Get full text

Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: A placebo-controlled trial by Tullis, D. Elizabeth, Burns, Jane L, Retsch-Bogart, George Z, Bresnik, Mark, Henig, Noreen R, Lewis, Sandra A, LiPuma, John J

“…Abstract Background Individuals with Burkholderia spp. infection have historically been excluded from efficacy trials of inhaled antibiotics, including…”
Get full text

Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease by Cornely, Oliver A., Maertens, Johan, Bresnik, Mark, Ebrahimi, Ramin, Dellow, Emma, Herbrecht, Raoul, Donnelly, J. Peter

“…Summary In 2008, the European Organisation for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) published revised definitions for diagnosing…”
Get full text

A safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic fever by Ellis, Michael, Bernsen, Roos, Ali-Zadeh, Hussein, Kristensen, Jorgen, Hedstrom, Ulla, Poughias, Lazaros, Bresnik, Mark, Al-Essa, Awad, A. Stevens, David

“…1 Department of Medicine, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain, UAE 2 Department of Community Medicine, Faculty of…”
Get full text

Liposomal Amphotericin B (L-AMB) Is Superior to Amphotericin B Deoxycholate (AmB-d) in Preventing Breakthrough Fungal Infections in Patients with Prolonged Neutropenia and Fever: Results of a Sub-Group Analysis of an Empirical Antifungal Therapy Trial by Cordonnier, Catherine, Walsh, Thomas J., Bresnik, Mark

“…In a trial of empirical antifungal therapy in persistently febrile neutropenic patients, L-AMB was shown to be comparable in overall efficacy with…”
Get full text

Liposomal Amphotericin B (L-AMB) as Initial Therapy for Invasive Filamentous Fungal Infections (IFFI): A Randomized, Prospective Trial of a High Loading Regimen vs. Standard Dosing (AmBiLoad Trial) by Cornely, Oliver A., Maertens, Johan, Bresnik, Mark, Herbrecht, Raoul

“…Background: L-AMB exhibits non-linear pharmacokinetics, with maximal values for Cmax and AUC achieved at a dose of 10 mg/kg/d. Maximal tolerated dose is >15…”
Get full text

Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection : A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial). Commentary by COMELY, Oliver A, MAERTENS, Johan, AOUN, Mickael, HORST, Heinz-August, THIEBAUT, Anne, RUHNKE, Markus, REICHERT, Dietmar, VIANELLI, Nicola, KRAUSE, Stefan W, OLAVARRIA, Eduardo, HERBRECHT, Raoul, ANAISSIE, E. J, BRESNIK, Mark, EBRAHIMI, Ramin, ULLMANN, Andrew J, BOUZA, Emilio, HEUSSEL, Claus Peter, LORTHOLARY, Olivier, RIEGER, Christina, BOEHME, Angelika

Get full text